The anticipated EPS of -$0.70 and revenue of $193.3 million for the quarter ending December 2025.Negative P/E ratio of -40.57 but potential growth indicated by revenue projections.Concerns over negative operating cash flow with an enterprise value to operating cash flow ratio of -91.91.Axsome Therapeutics, listed on NASDAQ:AXSM, is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is set to release its quarterly earnings on February 23, 2026. Wall ...

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) and in the TD Cowen 46th Annual Health Care Conference in Boston, MA (U.S.). Managing Director and Group CEO, Dr. Christian Behrenbruch, will take part in a fireside chat with Oppenheimer on Thursday, February 26, 2026 at 4:40 p.m. EST (Friday, Feb 27 at 8:40 a.m. AEDT). K ...

Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adoption of its core endocrinology products. Q4 was particularly significant, as the company achieved an operating profit of €10 million and generated €73 million in operating cash flow. This was largely driven by YORVIPATH, which brought in €477 million for the full year, and ...

Incyte Corporation (NASDAQ:INCY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 10, Incyte Corporation reported that the company’s Q4 2025 revenue climbed 28% to $1.51 billion, while full-year sales reached $5.14 billion. The company’s growth was largely propelled by its flagship product, Jakafi, which achieved annual sales of $3.093 billion, and the rapid expansion of Opzelura in the atopic dermatitis and vitiligo markets. The company’s core business, excluding Jakafi, ...

Insmed Inc. (NASDAQ:INSM) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. On January 23, Roth/MKM began coverage of Insmed Inc. (NASDAQ:INSM) with a Buy rating and a $212 price target. The firm pointed to Insmed’s solid position for further upside in 2026, with predictions that the company’s Brinsupri medication will continue to exceed market expectations. Illumina (ILMN) Jumps 24.8% on Earnings Beat Moreover, the firm assigned a 75% probability of success to the company’s Phase 3 EN ...

Company Overview - Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focused on developing therapies for rare diseases, known for its innovative approach to addressing unmet medical needs [1] - Competitors include other biotech firms specializing in rare diseases, such as Vertex Pharmaceuticals and BioMarin Pharmaceutical [1] Financial Performance - On February 19, 2026, Stifel Nicolaus set a price target of $205 for INSM, indicating a potential upside of 28.22% from the stock's price of $159.88 at that time, reflecting a strategic reassessment from a previous target of $212 [2] - The stock is currently trading at $161, showing a 6.54% increase with a recent price change of $9.89 [2] - Insmed's Q4 2025 earnings call provided insights into the company's financial health and strategic plans, covering key financial metrics such as revenue and profit margins [3] Stock Performance - The stock has shown significant volatility, with a daily range between $147.26 and $163.14 [4] - Over the past year, INSM has reached a high of $212.75 and a low of $60.40, indicating substantial price fluctuations [4] - The company's market capitalization is approximately $34.34 billion, with a trading volume of 4,921,823 shares, reflecting active investor interest [4]

Heerma attributed fourth-quarter momentum to several factors, including FILSPARI’s differentiated profile as a once-daily oral, non-immunosuppressive therapy; simplified REMS monitoring requirements ; and the publication of KDIGO guidelines . He also said adoption is increasing in IgAN patients with proteinuria levels below 1.5 grams per gram, consistent with guideline direction toward earlier intervention and lower targets. When asked to quantify what proportion of fourth-quarter patient start forms came f ...

Launching two additional products pending regulatory outcomes: Pixclara (Pixlumia in Europe) for glioblastoma and Zircaix for renal cancer.Continuing to grow approved products, including building on the launch of Gozetotide and the FDA approval of Gleolan in 2025.He also said the precision medicine business is more than a cash generator, calling it strategic validation of therapeutic targets, a way to streamline clinical trials, and an avenue to deepen relationships with physician stakeholders. Looking ahea ...

Core Insights - PTC Therapeutics reported significant growth in revenue driven by the launch of Sephience for phenylketonuria (PKU), achieving $92 million in the fourth quarter and $111 million since its launch in 2025 [1][4][7] - The company exceeded its revenue guidance for 2025, reporting total net product and royalty revenue of $831 million, up from the previous guidance of $750 million to $800 million [2][6] Financial Performance - For Q4 2025, PTC's total net product and royalty revenue was $263 million, contributing to a full-year total of $831 million [2][4] - The company ended 2025 with $1.95 billion in cash, following the monetization of Evrysdi royalties for $240 million upfront [6][22][23] - PTC guided for 2026 product revenue between $700 million and $800 million, indicating a growth of 19% to 36% compared to 2025 [24] Product Development and Approvals - Sephience received approvals in the U.S., E.U., and Japan, with early commercial momentum noted through broad uptake across various patient demographics [3][7][8] - The company plans to expand Sephience's commercial footprint internationally, targeting 20 to 30 countries by the end of 2026 [11][13] Market Dynamics - Payers have shown favorable early reimbursement for Sephience, with minimal barriers to access and long refill periods [9][10] - The company is addressing the needs of "lost to follow-up" adults, leveraging social media and community networks to re-engage patients [10] Pipeline Updates - PTC is advancing its pipeline with Votoplam for Huntington's disease, with a phase III trial expected to start in H1 2026 [5][18] - For Vatiquinone, an additional study is required for NDA resubmission, with plans to align on the protocol with the FDA [19] Other Revenue Streams - The Duchenne muscular dystrophy (DMD) franchise contributed $66 million in Q4, with Evrysdi royalties generating $79 million [14][15] - The company continues to face challenges in the DMD market due to increased generic competition [15]

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years. On February 6, Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia to $4 from $6 and kept an Overweight rating. This adjustment was made as part of a broader review of commercial-stage companies, with the firm updating estimates and price targets following several year-end preliminary reports and ahead of official Q4 2025 results. In Q3, Akebia Therapeutics Inc. (NASDAQ:AKBA) ...